Los Angeles, CA, United States of America

Antoni Ribas

This inventor holds 16 USPTO granted patents and 8 published patent applications and 1 EPO patent, primarily in Cancer Immunotherapy. Top assignees: University of California, California Institute of Technology, Nektar Therapeutics. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Antoni Ribas. Retrieved from https://idiyas.com/inventor/antoni-ribas

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 8)

% Patents Active = 81.3

EPO Patents = 1 (Patent Applications = 14)

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 125(Granted Patents)

Company Filing History:

14 out of 16,048

University of California

patents

4 out of 4,632

California Institute of Technology

University of Pennsylvania

patents

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

T Cell Receptors

Melanoma Treatment

PD-1 Therapy

Oncolytic Viral Delivery

Adoptive Cell Transfer

Interleukin-2

Immunotherapy

Stem Cell Reprogramming

Cancer Assessment

Targeted Therapy

MHC Molecules

Detection Methods

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12661401 - SELECTIVE STIMULATION OF T CELLS IN SOLID TUMORS USING ONCOLYTIC VIRAL DELIVERY OF ORTHOGONAL IL-2 (2026-06-23),

2. 12617834 - COMPOSITION OF NY-ESO-1-SPECIFIC T CELL RECEPTORS RESTRICTED ON MULTIPLE MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES (2026-05-05),

3. 12398193 - Targeted replacement of endogenous T cell receptors (2025-08-26),

4. 12213977 - Methods and compositions for treating melanoma (2025-02-04),

5. 11590171 - Targeted replacement of endogenous T cell receptors (2023-02-28),

6. 11331346 - Targeted replacement of endogenous T cell receptors (2022-05-17),

7. 11318164 - Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy (2022-05-03),

8. 11275080 - Methods for stratifying non-responders to therapies that block PD1/PDL1 axis (2022-03-15),

9. 11083753 - Targeted replacement of endogenous T cell receptors (2021-08-10),

10. 11033584 - Targeted replacement of endogenous T cell receptors (2021-06-15),

11. 10744116 - Detection and treatment of anti-PD-1 therapy resistant metastatic melanomas (2020-08-18),

12. 10711312 - Methods for immunotherapy-based treatment and assessment of cancer (2020-07-14),

13. 10201597 - Codon-optimized lentiviral vector for stem cell reprogramming (2019-02-12),

14. 8552150 - MART-1 T cell receptors (2013-10-08),

15. 8394590 - Capture agents and related methods and systems for detecting and/or sorting targets (2013-03-12),

Title: The Innovative Mind of Antoni Ribas

Introduction

Antoni Ribas is a prominent inventor based in Los Angeles, California, recognized for his significant contributions to the field of melanoma treatment. With a remarkable portfolio of 13 patents, Ribas has been at the forefront of developing novel therapeutic methods aimed at combating this aggressive skin cancer.

Latest Patents

Among his most recent innovations are the patents titled "Methods and Compositions for Treating Melanoma" and "Targeted Replacement of Endogenous T Cell Receptors." The first patent describes a therapeutic method specifically designed for patients diagnosed with melanoma, particularly those resistant to existing therapies. It involves administering a composition containing a ferroptosis-inducing agent or other dedifferentiated melanoma-targeting agents. In the second patent, Ribas outlines advanced methods and compositions for editing the genome of human T cells, enhancing their ability to fight cancer by incorporating heterologous T cell receptor (TCR) chains into the T cell's genome.

Career Highlights

Antoni Ribas has had a distinguished career, working with esteemed institutions, including the University of California and the California Institute of Technology. His innovative research and dedication to improving cancer therapies have made a significant impact within the medical community.

Collaborations

Throughout his career, Ribas has collaborated with other notable professionals in the field, including Theodore Lee Roth and Eric Shifrut. Their combined expertise has further advanced the development of groundbreaking treatments for melanoma.

Conclusion

Antoni Ribas continues to be a trailblazer in oncology, utilizing his inventive spirit to create solutions that address critical health challenges. As medical advancements evolve, his contributions will undoubtedly play a crucial role in shaping the future of cancer treatment.

Profile summary based on public USPTO records.